These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2897695)

  • 1. Use of analogs of LH-RH and somatostatin for the treatment of hormone dependent cancers.
    Redding TW; Schally AV
    Prog Clin Biol Res; 1988; 262():217-40. PubMed ID: 2897695
    [No Abstract]   [Full Text] [Related]  

  • 2. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Schally AV; Redding TW
    Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7275-9. PubMed ID: 2890164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian golden hamsters with D-Trp-6-LH-RH and somatostatin analogue RC-160 microcapsules.
    Zalatnai A; Schally AV
    Cancer Res; 1989 Apr; 49(7):1810-5. PubMed ID: 2564312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin].
    Schally AV
    An R Acad Nac Med (Madr); 2004; 121(3):493-500. PubMed ID: 15751842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy targeted to cancers through tumoral hormone receptors.
    Schally AV; Nagy A
    Trends Endocrinol Metab; 2004 Sep; 15(7):300-10. PubMed ID: 15350601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [History of clinical studies on hypothalamic hormone analogs in Mexico].
    Schally AV; González Bárcena D
    Gac Med Mex; 2006; 142(4):315-25. PubMed ID: 17022307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms.
    Schally AV; Redding TW; Comaru-Schally AM
    Cancer Treat Rep; 1984 Jan; 68(1):281-9. PubMed ID: 6362868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [LHRH analogs as monthly depot preparations in treatment of advanced prostate cancer].
    Urologe A; 1991 May; 30(3 Suppl):2-3. PubMed ID: 1746071
    [No Abstract]   [Full Text] [Related]  

  • 9. Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin.
    Kadar T; Redding TW; Ben-David M; Schally AV
    Proc Natl Acad Sci U S A; 1988 Feb; 85(3):890-4. PubMed ID: 2893378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decrease in prolactin receptor affinity in the rat mammary tumor model after treatment with analogs of somatostatin and LH-RH.
    Kadar T; Redding TW; Ben-David M; Schally AV
    Mater Med Pol; 1988; 20(4):219-23. PubMed ID: 2907923
    [No Abstract]   [Full Text] [Related]  

  • 11. Hypothalamic hormones and cancer.
    Schally AV; Comaru-Schally AM; Nagy A; Kovacs M; Szepeshazi K; Plonowski A; Varga JL; Halmos G
    Front Neuroendocrinol; 2001 Oct; 22(4):248-91. PubMed ID: 11587553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of hormone-dependent neoplasms (prostatic cancer, breast cancer). The place of LH-RH analogs].
    Charron M
    Soins; 1991 Sep; (552):61-4. PubMed ID: 1957225
    [No Abstract]   [Full Text] [Related]  

  • 14. Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin.
    Szende B; Zalatnai A; Schally AV
    Proc Natl Acad Sci U S A; 1989 Mar; 86(5):1643-7. PubMed ID: 2564204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete androgen blockade for the treatment of prostate cancer.
    Labrie F; Dupont A; Belanger A
    Important Adv Oncol; 1985; ():193-217. PubMed ID: 3916740
    [No Abstract]   [Full Text] [Related]  

  • 16. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination.
    Szepeshazi K; Milovanovic S; Lapis K; Groot K; Schally AV
    Breast Cancer Res Treat; 1992; 21(3):181-92. PubMed ID: 1355375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histologic changes in the rat prostate cancer model after treatment with somatostatin analogs and D-Trp-6-LH-RH.
    Zalatnai A; Paz-Bouza JI; Redding TW; Schally AV
    Prostate; 1988; 12(1):85-98. PubMed ID: 2894651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Responsiveness of the hamster pancreatic cancer to treatment with microcapsules of D-Trp-6-LH-RH and somatostatin analog RC-160. Histological evidence of improvement.
    Zalatnai A; Schally AV
    Int J Pancreatol; 1989 Mar; 4(2):149-60. PubMed ID: 2566638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of the chronic administration of LH-RH agonist on the oral glucose tolerance test in patients with prostatic carcinoma.
    González-Bárcena D; Pérez-Sánchez P; Hernández-Meza AR; Rangel-García N; Graef-Sánchez A; Comaru-Schally AM; Schally AV
    Arch Invest Med (Mex); 1987; 18(4):273-8. PubMed ID: 2969222
    [No Abstract]   [Full Text] [Related]  

  • 20. Antitumor effects of analogs of hypothalamic hormones in endocrine-dependent cancers.
    Schally AV; Comaru-Schally AM; Redding TW
    Proc Soc Exp Biol Med; 1984 Mar; 175(3):259-81. PubMed ID: 6141569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.